menu
    • menu
    [{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Karyopharm Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Mezigdomide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Bristol Myers Squibb \/ Karyopharm Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Bristol Myers Squibb \/ Karyopharm Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals for Mezigdomide

    Menu

    Mezigdomide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bristol Myers Squibb

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Bristol Myers Squibb

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mezigdomide,Selinexor

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent ...

                            Details : The collaboratin aims to evaluate the investigational cereblon E3 ligase modulator agent mezigdomide in combination with Karyopharm's selinexor, an approved first-in-class inhibitor of XPO1, plus dexamethasone in patients with relapsed/refractory multipl...

                            Brand Name : BMS-986348

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 30, 2023

                            Lead Product(s) : Mezigdomide,Selinexor

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Karyopharm Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth